<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372057</url>
  </required_header>
  <id_info>
    <org_study_id>VS-0145-225</org_study_id>
    <nct_id>NCT03372057</nct_id>
  </id_info>
  <brief_title>A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)</brief_title>
  <official_title>A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual
      inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma
      (PTCL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has 2 phases, a Dose Optimization Phase and an Expansion Phase.

      In the Dose Optimization Phase, patients will be randomly assigned to 1 of 2 study cohorts,
      as follows:

        -  Cohort 1: Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a
           per-patient basis to 50 mg and then 75 mg, based on the patient's response to and
           tolerance of therapy, in 28-day cycles.

        -  Cohort 2: Duvelisib 75 mg PO BID, administered in 28-day cycles .

      A total of 20 patients will be enrolled in the Dose Optimization Phase, with 10 patients per
      cohort. Based on the safety and activity data obtained in the Dose Optimization Phase of the
      study, the Expansion Phase dose of Duvelisib will be determined.

      In the Expansion Phase, approximately 90-100 patients may be enrolled and will receive
      Duvelisib dose in 28-day cycles as determined in Dose Optimization Phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From start of treatment to first documented response, assessed up to 2 cycles (58 days)</time_frame>
    <description>Best response of CR or PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>From start of treatment until disease progression or unacceptable toxicity, assessed up to 2 cycles (58 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v4.0</measure>
    <time_frame>From start of treatment to end of treatment plus 30 days; 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from the first documentation of response to first documentation of progressive disease or death due to any cause, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Time from start of treatment to first documentation of progression or date of death from any cause, whichever came first, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Greater than or equal to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From start of treatment until death, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who receive the optimal dose of duvelisib</measure>
    <time_frame>From start of treatment to end of cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Optimization Phase: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization Phase: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib 75 mg PO BID, administered in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duvelisib administered in 28-day cycles (dose determined in Optimization Phase)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.</description>
    <arm_group_label>Dose Optimization Phase: Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>Duvelisib PO 75 mg BID in 28-day cycles.</description>
    <arm_group_label>Dose Optimization Phase: Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duvelisib</intervention_name>
    <description>Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase)</description>
    <arm_group_label>Expansion Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years of age

          2. Diagnosis of one of the following histologic subtypes of PTCL,
             pathologically-confirmed, as defined by the World Health Organization:

               1. Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS);

               2. Angioimmunoblastic T-cell lymphomas (AITL);

               3. Anaplastic large cell lymphoma (ALCL); or

               4. Natural-killer/T-cell lymphoma (NKTL)

          3. Received at least 2 cycles of one prior regimen administered with curative intent and
             one of the following:

               1. failed to achieve at least a partial response after 2 or more cycles;

               2. failed to achieve a complete response after 6 or more cycles; and/or

               3. progressed after an initial response

          4. For patients with CD30+ ALCL, failed or are ineligible or intolerant to brentuximab
             vedotin

          5. Measurable disease as defined by IWG for PTCL, i.e., at least 1 measurable disease
             lesion &gt; 1.5 cm in at least one dimension by 18FDG-PET-CT, MRI, or diagnostic CT

        Exclusion Criteria:

          1. Clinical evidence of transformation to a more aggressive subtype of lymphoma

          2. Received prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor

          3. Known central nervous system involvement by PTCL

          4. Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic
             steroids &gt; 20 mg of prednisone (or equivalent) once daily (QD)

          5. Ongoing treatment for systemic bacterial, fungal, or viral infection at Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jasminder Soto</last_name>
    <phone>781-292-4250</phone>
    <email>jsoto@verastem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah Lloyd</last_name>
    <phone>781-292-4230</phone>
    <email>dlloyd@verastem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Aranki</last_name>
      <email>garanki@coh.org</email>
    </contact>
    <investigator>
      <last_name>Jasmine Zain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Johnson</last_name>
      <email>blakej@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Pinter-Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Catala</last_name>
      <email>MCatala@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Mead, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Bearden</last_name>
      <email>jeffrey.bearden1@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Pro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Jeter</last_name>
      <email>Erin_Jeter@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Eric Jacobsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen McDaniels, BS</last_name>
      <email>k.mcdaniels@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Neha Mehta-Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Bahgat</last_name>
      <email>bahgata@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Steven Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yelena Lerman</last_name>
      <email>ylerman@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlyn Burrows</last_name>
      <email>Kaitlyn_Burrows@URMC.Rochester.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carla Casulo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Smith</last_name>
      <email>April.Smith@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark LaRocque</last_name>
      <email>mlarocque@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Alan Skarbnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univeristy</name>
      <address>
        <city>Columbia</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hema Hema</last_name>
      <email>Hemalatha.rao@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Brammer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>T-cell Lymphoma</keyword>
  <keyword>Relapse</keyword>
  <keyword>Refractory</keyword>
  <keyword>PI3K-δ,γ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

